^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | brusatol (NRF2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways
Published date:
07/20/2020
Excerpt:
Results showed that brusatol exhibited potent inhibitory effects in a dose-dependent manner either in BT-474, SK-OV-3, or SK-BR-3 cell line which overexpressed HER2 (Figure 1(a)).
DOI:
https://doi.org/10.1155/2020/9867595
